Wells Fargo & Company Trims Clorox (NYSE:CLX) Target Price to $120.00

Clorox (NYSE:CLXGet Rating) had its target price trimmed by Wells Fargo & Company from $130.00 to $120.00 in a research report report published on Tuesday morning, Stock Target Advisor reports. The firm currently has an underweight rating on the stock.

CLX has been the subject of a number of other research reports. DA Davidson lowered their price target on Clorox from $127.00 to $123.00 in a report on Tuesday, May 3rd. Barclays lowered their price target on Clorox from $126.00 to $115.00 and set an underweight rating for the company in a report on Monday, May 23rd. Deutsche Bank Aktiengesellschaft lowered their price target on Clorox from $145.00 to $132.00 in a report on Tuesday. StockNews.com initiated coverage on Clorox in a report on Thursday, March 31st. They set a hold rating for the company. Finally, The Goldman Sachs Group lowered their target price on Clorox from $145.00 to $127.00 in a report on Tuesday, March 29th. Nine analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Reduce and an average price target of $140.69.

NYSE:CLX opened at $140.11 on Tuesday. The stock has a fifty day moving average price of $142.50 and a 200-day moving average price of $151.47. The company has a market cap of $17.24 billion, a price-to-earnings ratio of 37.97, a PEG ratio of 4.31 and a beta of 0.18. The company has a debt-to-equity ratio of 3.28, a quick ratio of 0.40 and a current ratio of 0.71. Clorox has a fifty-two week low of $120.50 and a fifty-two week high of $191.75.

Clorox (NYSE:CLXGet Rating) last released its earnings results on Monday, May 2nd. The company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.34. The firm had revenue of $1.81 billion during the quarter, compared to the consensus estimate of $1.81 billion. Clorox had a return on equity of 92.98% and a net margin of 6.44%. During the same period in the prior year, the company posted $1.62 EPS. Research analysts predict that Clorox will post 4.16 EPS for the current fiscal year.

In related news, Director A D. David Mackay sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $140.63, for a total transaction of $140,630.00. Following the sale, the director now owns 600 shares in the company, valued at approximately $84,378. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eric H. Reynolds sold 585 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the sale, the chief operating officer now owns 17,289 shares in the company, valued at approximately $2,676,855.87. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.

Several institutional investors have recently made changes to their positions in CLX. Federated Hermes Inc. boosted its position in shares of Clorox by 71,909.5% during the 1st quarter. Federated Hermes Inc. now owns 1,044,858 shares of the company’s stock valued at $145,267,000 after purchasing an additional 1,043,407 shares in the last quarter. Nuance Investments LLC boosted its holdings in Clorox by 224.7% in the first quarter. Nuance Investments LLC now owns 1,142,363 shares of the company’s stock worth $158,823,000 after acquiring an additional 790,505 shares in the last quarter. Verity Asset Management Inc. bought a new position in Clorox in the first quarter worth approximately $192,000. Candlestick Capital Management LP boosted its holdings in Clorox by 171.4% in the first quarter. Candlestick Capital Management LP now owns 700,000 shares of the company’s stock worth $97,321,000 after acquiring an additional 442,082 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Clorox by 3.2% in the first quarter. BlackRock Inc. now owns 11,117,522 shares of the company’s stock worth $1,545,669,000 after acquiring an additional 342,680 shares in the last quarter. Institutional investors own 77.28% of the company’s stock.

Clorox Company Profile (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

Featured Articles

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.